Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
February 26, 2004
The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells
Sarah L Pogue, Benjamin T Preston, Joseph Stalder, et al.
Clinical Pharmacology in Drug Development
|
August 4, 2023
Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects
Devki D Sukhtankar, Li-Wen Chang, Cheng-Yuan Tsai, et al.
Cancer Immunology, Immunotherapy : CII
|
February 15, 2002
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines
Pina M Cardarelli, Maire Quinn, Dana Buckman, et al.
Inflammation
|
April 9, 2002
Inhibition of tyrosine kinases blocks adhesion-induced T-cell coactivation without interfering with T-cell adhesion to endothelial cell-surface ligands
Dawn M Nowlin, Pina M Cardarelli, Lynn Young, et al.
Drug Discovery Today
|
November 19, 2013
Antibody-drug conjugates: current status and future directions
Heidi L Perez, Pina M Cardarelli, Shrikant Deshpande, et al.
Arthritis and Rheumatism
|
December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Michael Yellin, Igor Paliienko, Andra Balanescu, et al.
Cancer Chemotherapy and Pharmacology
|
November 19, 2015
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
Taofeek Kunle Owonikoko, Arif Hussain, Walter Michael Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2012
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies
Michelle R Kuhne, Tanya Mulvey, Blake Belanger, et al.
Bioorganic & Medicinal Chemistry
|
April 9, 2002
Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist
Ila Sircar, Kristjan S Gudmundsson, Richard Martin, et al.
Cancer Immunology, Immunotherapy : CII
|
August 7, 2009
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
Pina M Cardarelli, Chetana Rao-Naik, Sharline Chen, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
February 26, 2004
The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells
Sarah L Pogue, Benjamin T Preston, Joseph Stalder, et al.
Clinical Pharmacology in Drug Development
|
August 4, 2023
Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects
Devki D Sukhtankar, Li-Wen Chang, Cheng-Yuan Tsai, et al.
Cancer Immunology, Immunotherapy : CII
|
February 15, 2002
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines
Pina M Cardarelli, Maire Quinn, Dana Buckman, et al.
Inflammation
|
April 9, 2002
Inhibition of tyrosine kinases blocks adhesion-induced T-cell coactivation without interfering with T-cell adhesion to endothelial cell-surface ligands
Dawn M Nowlin, Pina M Cardarelli, Lynn Young, et al.
Drug Discovery Today
|
November 19, 2013
Antibody-drug conjugates: current status and future directions
Heidi L Perez, Pina M Cardarelli, Shrikant Deshpande, et al.
Arthritis and Rheumatism
|
December 8, 2011
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Michael Yellin, Igor Paliienko, Andra Balanescu, et al.
Cancer Chemotherapy and Pharmacology
|
November 19, 2015
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
Taofeek Kunle Owonikoko, Arif Hussain, Walter Michael Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2012
BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies
Michelle R Kuhne, Tanya Mulvey, Blake Belanger, et al.
Bioorganic & Medicinal Chemistry
|
April 9, 2002
Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist
Ila Sircar, Kristjan S Gudmundsson, Richard Martin, et al.
Cancer Immunology, Immunotherapy : CII
|
August 7, 2009
A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
Pina M Cardarelli, Chetana Rao-Naik, Sharline Chen, et al.
Page
of 3